Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital (MGH) presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland.
Please join us for a presentation on plans for an ALS Platform Trial through the NEALS Consortium. The NEALS satellite meeting will be held on Sunday, December 9th from 7:15 – 8:15 AM.
Congratulations to NeuroBANK for winning a Bio-IT Best Practices award for a Patient-Centric Platform for Clinical Research.
There will be a NEALS Consortium satellite meeting at the 70th AAN Annual Meeting on Wednesday, April 25, 2018.
The NEALS Consortium is now accepting nominations for the 2018 ALS Clinical Research Learning Institute (CRLI)! Applications will be accepted through June 7, 2018.
Congratulations to NEALS Co-Chair Dr. Timothy Miller, winner of the 2018 Sheila Essey Award!
NEALS has established various subcommittees focused on advancing ALS research and patient care. In an effort to keep our members and subscribers informed about what these focus groups are working on, NEALS will distribute a semi-annual update on committee activities.
The CRLI is a two-day program dedicated to educating attendees on clinical research and therapy development and empowering this group to be even more effective research advocates. Local patients, caregivers, surviving spouses and family, and patient-caregiver pairs are encouraged to apply by May 15, 2018.
Summary recommendations from the NEALS bulbar subcommittee symposium.
FORTITUDE-ALS is a clinical trial of an investigational oral drug for the treatment of amyotrophic lateral sclerosis (ALS). This clinical trial is now enrolling participants in both the United States and Canada.
